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Abstract
Objectives
HIV-induced immunodeficiency is associated with metabolic abnormalities and systemic
inflammation. We investigated the effect of antiretroviral therapy (ART) on restoration of
insulin sensitivity, markers of immune activation and inflammation.
Methods
Immunological, metabolic and inflammatory status was assessed at antiretroviral therapy
initiation and three years later in 208 patients from the ANRS-COPANA cohort. Patients
were compared according to their pre-ART CD4+ cell count (group 1: 200/mm3, n = 66 vs.
group 2: > 200/mm3, n = 142).
Results
Median CD4+ cell count increased in both groups after 3 years of successful ART but
remained significantly lower in group 1 than in group 2 (404 vs 572 cells/mm3). Triglyceride
and insulin levels were higher or tended to be higher in group 1 than in group 2 at ART initia-
tion (median: 1.32 vs 0.97 mmol/l, p = 0.04 and 7.6 vs 6.8 IU, p = 0.09, respectively) and
remained higher after three years of ART (1.42 vs 1.16 mmol/L, p = 0.0009 and 8.9 vs 7.2
IU, p = 0.01). After adjustment for individual characteristics and antiretroviral therapy
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regimens (protease inhibitor (PI), zidovudine), insulin levels remained significantly higher in
patients with low baseline CD4+ cell count. Baseline IL-6, sCD14 and sTNFR2 levels were
higher in group 1 than in group 2. Most biomarkers of immune activation/inflammation
declined during ART, but IL-6 and hsCRP levels remained higher in patients with low base-
line CD4+ cell count than in the other patients (median are respectively 1.4 vs 1.1 pg/ml, p =
0.03 and 2.1 vs 1.3 mg/ml, p = 0.07).
Conclusion
After three years of successful ART, low pretreatment CD4+ T cell count remained associ-
ated with elevated insulin, triglyceride, IL-6 and hsCRP levels. These persistent metabolic
and inflammatory abnormalities could contribute to an increased risk of cardiovascular and
metabolic disease.
Introduction
Altered glucose metabolism, including insulin resistance, is more frequent in HIV-infected
patients than in the general population and is associated with an excess risk of diabetes [1].
Insulin resistance, generally assessed by increased insulin levels, has been variously attributed
to certain antiretroviral drugs (particularly some nucleoside reverse-transcriptase inhibitors
(NRTIs) and protease inhibitors (PIs)), antiretroviral therapy (ART)-induced lipodystrophy,
and classical risk factors such as age, sex, body mass index and genetic susceptibility [1–9]. In
addition, leptin is strongly associated with body fat mass, and adiponectin is a major contribu-
tor to insulin sensitivity. Thus the leptin/adiponectin ratio has been shown to be a powerful
surrogate marker of insulin resistance in the general population [10]. As well, in HIV-infected
patients, we have previously observed that the adiponectin/leptin ratio was associated with
insulin sensitivity [11]. Persistent moderate systemic inflammation in HIV-infected patients
on ART appears to increase the risk of diabetes [12–14], an association not observed before
ART [14, 15]. Markers of systemic inflammation and immune activation are usually elevated
in HIV-infected patients, both before and during ART [16–21]. HIV-infected patients show
increased microbial translocation, a phenomenon associated with immune activation and
inflammation [22] and also with insulin resistance and lipid disorders [23]. Elevated levels of
inflammatory markers have also been linked to higher all-cause morbidity, including cardio-
vascular diseases, and mortality [24–28].
Low CD4+ T cell counts at ART initiation or during follow-up, and a low CD4 nadir, have
been linked to an increased risk of new-onset diabetes [2, 3, 29, 30]. We have previously
reported an increased risk of insulin resistance among severely immunodeficient ART-naïve
patients enrolled in the ANRS CO9 COPANA cohort [15]. The impact of sustained ART on
restoration of insulin sensitivity is unknown.
The main objective of this study was to investigate changes in insulin sensitivity and bio-
markers of inflammation/immune activation after ART initiation in patients with chronic HIV
infection, according to their pretreatment CD4+ T cell count. We analyzed the impact of
immune restoration and persistent inflammation on insulin sensitivity.
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Methods
Study design and population
ANRS CO9 COPANA is an ongoing prospective cohort study conducted in 37 hospitals in
France. Eight hundred recently diagnosed (<12 months) ART-naive HIV-infected patients
were recruited to the cohort between 2004 and 2008. The cohort is funded by Inserm-ANRS
and the study was approved by the Paris-Cochin Ethics Committee in July 2003. The research
was conducted in accordance with the Declaration of Helsinki; All the participants gave their
written informed consent. Socio-demographic, clinical and biological data were collected at
enrolment and every 6 months thereafter. Each patient's history of AIDS-defining illnesses,
cardiovascular disease, cancer, diabetes or other diseases, and HBV and HCV serostatus were
recorded, along with CD4+ and CD8+ T cell counts and plasma HIV-1 RNA viral load (VL).
Fasting total cholesterol, high-density lipoprotein (HDL)- and low-density lipoprotein (LDL)-
cholesterol, triglyceride and glucose levels were measured with standard procedures in each
center at least once a year.
For this study, we selected the 208 patients who took ART continuously for at least three
years and had available frozen samples at ART initiation and three years later. We compared
two groups based on the CD4+ T cell count at ART initiation: 66 patients with 200 CD4+
cells/mm3 (group 1) and 142 patients with> 200 CD4+ cells/mm3 (group 2).
Measurements
Clinical and laboratory data were collected before ART initiation and during treatment. Cryo-
preserved serum and plasma were used for centralized measurements at Tenon Hospital Bio-
chemistry Department (Paris, France). Plasma glucose (hexokinase) and insulin
(chemiluminescence immunoassay) were measured on the Architect1 Ci8200 analyzer
(Abbott). High-sensitivity (hs) CRP was measured by immunonephelometry on an IMMAGE
analyzer (Beckman-Coulter). High-sensitivity (hs) IL-6, sCD14, sCD163, sTNFRI and II were
measured with enzyme-linked immunosorbent assays (ELISA) (Quantikine1, R&D Systems).
Impaired fasting glucose metabolism was defined, in the absence of diabetes, by at least one
fasting glycemia value between 5.6 and 6.9 mmol/l. Diabetes was recorded if the patient was
receiving antidiabetic treatment or if the fasting glucose was 7 mmol/l. ART regimens and
treatments for comorbidities were recorded every 6 months. To better take into account actual
ART drugs exposure during the 3-year study period, we distinguished never-exposed patients,
patients who stopped ART drugs for more than 6 months before the 3-year endpoint, and
patients still taking ART.
Statistical analyses
To study the impact of immunodeficiency on insulin sensitivity and inflammatory markers,
the patients were categorized according to their CD4+ T cell count at ART initiation ( 200/
mm3 versus> 200/mm3). Continuous variables were recorded as medians and 25th to 75th per-
centiles (IQR), and categorical variables as percentages. Non-parametric Wilcoxon tests were
used to compare continuous variables, and the χ2 or Fisher’s test was used for categorical vari-
ables. Pearson correlation coefficients were used to estimate the relation between continuous
variables. Comparisons of anthropometric and lipid values between groups 1 and 2 were
adjusted for sex in multiple logistic or linear regression models. Multivariate linear regression
models were used to examine the influence of the following variables on insulin levels after
three years of ART: age and insulin levels at ART initiation, sex, BMI, and ongoing PI or ZDV
exposure after three years of ART. Reported p values are those estimated from the Wald test
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values by SAS GLM. SAS software version 9.3 (SAS institute, Cary, NC, USA) was used for all
analyses.
Results
Baseline Characteristics
At ART initiation, the median age of the 208 patients was 38 years (IQR 46–32); 30% of the
patients were women (n = 63), and 38% originated from sub-Saharan Africa (n = 78). The
median CD4+ T cell count was 248/mm3 (IQR 308–156), and 32% of the patients (n = 66) had
a pre-ART count 200 cells/mm3. Median viral load (VL) was 4.8 log10 copies/mL (IQR: 5.4–
4.3). Eight patients (4%) were coinfected with HCV and 4 (2%) with HBV.
The patients' characteristics are shown in Table 1 according to their CD4+ T cell count at
ART initiation. Patients in group 1 (pre-ART CD4+ T cell count 200/mm3) were slightly
older than patients in group 2 (pre-ART CD4+ T cell count> 200/mm3) (38.5 versus 37.0
years, p = 0.09) and, as expected, had experienced more AIDS-defining events (31.8% versus
3.5%, p<0.0001). There was no difference in gender, geographic origin, HBV and HCV status,
and current smoking between the groups. The differences in the proportions of HBV, HCV
coinfected patients and current smokers remained not significant between the groups during
the study period (data not shown). In the entire study group, only 1 patient reported current
drug injection which precludes any comparison.
Immunovirological response (Table 1)
At ART initiation the median CD4+ T cell count was 92/mm3 in group 1 and 283/mm3 in
group 2 and the CD4+/CD8+ ratio was lower in group 1 than in group 2 (p<0.0001). After
three years of ART, the CD4+ T cell count and the CD4+/CD8+ ratio increased in both groups
but remained significantly lower in group 1 than in group 2 (p<0.0001 for both), whereas the
proportion of patients with undetectable viral load was similarly high in the two groups (89.4%
and 92.3%, respectively).
For most of the 208 patients, first-line ART combined 2 nucleoside reverse-transcriptase
inhibitors (NRTI) with either a PI (60.6%) or a non-nucleoside reverse-transcriptase inhibitor
(NNRTI) (31.3%). The proportion of patients taking a PI was lower at three years (49.0%),
owing to switches to other regimens. Patients with initial CD4+ T cell counts 200/mm3, who
were more likely to start treatment before 2006, were more often prescribed zidovudine (ZDV)
(42.4% versus 21.8%, p = 0.002) and less often tenofovir (TDF) (42.4% versus 59.1%, p = 0.02)
than patients with higher initial CD4+ cell counts. The proportion of patients whose first-line
ART regimen contained abacavir (ABC) was low in both groups (9% in group 1 and 14% in
group 2, p = 0.31).
After three years of ART, the proportion of patients still receiving ZDV was lower in both
groups than at baseline but remained higher in group 1 than in group 2 (27.3% versus 7.0%,
p<0.0001). ZDV was mainly replaced by TDF (48.5% in group 1 versus 70.4% in group 2,
p = 0.002) and less often by ABC (16.7% and 19.7%, p = 0.60).
Metabolic outcomes
Table 1 shows lipid and glucose metabolic status at ART initiation and after three years of con-
tinuous ART in the two groups.
BMI did not differ significantly according to the initial CD4+ cell count, either before or
after three years of ART (p values adjusted for sex = 0.27 and 0.12, respectively). However,
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Table 1. Main parameters and their evolution, according to CD4 T-cell count at ART initiation, at three years-ART.
ART initiation After 3 years of ART Comparison of
evolution2
CD4+ T-cell counts at ART initiation CD4+ T-cell counts at ART initiation
Characteristics  200 (n = 66)
group 1
> 200 (n = 142)
group 2
p  200 (n = 66)
group 1
> 200 (n = 142)
group 2
p p
Baseline Characteristics
Female, % (n) 33.3 (22) 28.9 (41) 0.51
Age at ART initiation,
years
38.5 (33.8; 47.5) 37.0 (30.8; 45.1) 0.09
From sub-Saharan Africa 43.9 (29) 34.5 (49) 0.19
Clinical AIDS, % (n) 31.8 (21) 3.5 (5) <0.0001
Hepatitis C, % (n) 3.0 (2) 4.2 (6) 0.68
Hepatitis B, % (n) 3.0 (2) 1.4 (2) 0.59
Current smoking, % (n) 25 (16) 29 (41) 0.49
Evolution from baseline
CD4+ T-cell counts, cells/
mm3
92 (51; 142) 283 (247; 329) <0.0001 404 (304; 550) 572 (465; 692) <0.0001 0.08
CD4/CD8 Ratio 0.1 (0.1; 0.25) 0.3 (0.2; 0.5) <0.0001 0.55 (0.33; 0.85) 0.85 (0.63; 1.16) <0.0001 0.04
HIV-1 RNA levels, log10
cop/ml
5.2 (4.8; 5.7) 4.7 (4.1; 5.2) <0.0001
HIV-1 RNA levels <50 cop/
ml, % (n)
89.4 (59) 92.3 (131) 0.49 0.77
Treatment combination 0.20 0.45
2 NRTI + 1 PI/r 68.2 (45) 57.0 (81) 53.0 (35) 47.2 (67)
2 NRTI + 1 NNRTI 22.7 (15) 35.2 (50) 33.3 (22) 42.3 (60)
Other 9.1 (6) 7.8 (11) 13.6 (9) 10.6 (15)
ZDV- containing regimen,
% (n)
42.4 (28) 21.8 (31) 0.002 27.3 (18) 7.0 (10) <0.0001
Total Cholesterol, mmol/L 4.07 (3.50; 4.70) 4.27 (3.64; 4.88) 0.12 1 5.19 (1.09; 6.01) 5.04 (4.47; 5.67 0.30 1 0.181
HDL-cholesterol, mmol/L 0.93 (0.82; 1.18) 1.09 (0.83; 1.29) 0.01 1 1.20 (0.97; 1.63) 1.31 (1.09; 1.64) 0.15 1 0.751
LDL-cholesterol, mmol/L 2.40 (1.94; 2.89) 2.66 (2.13; 3.10) 0.06 1 3.20 (2.09; 3.69) 3.06 (2.58; 3.57) 0.54 1 0.09 1
Triglycerides, mmol/L 1.32 (0.91; 1.97) 0.97 (0.79; 1.49) 0.04 1 1.42 (1.02; 2.19) 1.16 (0.88; 1.60) 0.0009 1 0.81 1
BMI, kg/m2 22.8 (20.1; 25.7) 23.3 (21.6; 25.6) 0.27 1 24.7 (22.6; 28.0) 23.7 (21.6; 27.1) 0.12 1 <0.00011
Impaired fasting glucose
(IFG), % (n)
10.9 (7) 14.6 (20) 0.51 1 10.6 (7) 18.3 (26) 0.18 1 0.99 1
Diabetes, % (n) 8.4 (6) 6.6 (9) 0.43 1 10.6 (7) 8.5 (12) 0.57 1 0.57 1
Fasting glucose, mmol/l 4.9 (4.4; 5.4) 5.1 (4.6; 5.5) 0.08 4.9 (4.3; 5.6) 5.1 (4.7; 5.7) 0.09 0.44
Fasting insulin, mUI/L 7.6 (5.2; 17.3) 6.8 (4.9; 9.0) 0.09 8.9 (5.5; 15.1) 7.2 (4.8; 9.5) 0.01 1.00
Leptin, ng/mL 4.4 (1.7; 13.1) 4.1 (1.7; 10.2) 0.97 1 7.1 (2.8; 13.7) 5.2 (2.2; 9.6) 0.06 1 0.03
Adiponectin, ng/L 4.2 (2.9; 6.9) 4.5 (3.0; 5.7) 0.10 1 4.2 (2.9; 6.2) 4.8 (3.4; 6.8) 0.10 1 0.006
Leptin/Adiponectin ratio 1.03 (0.44; 2.54) 1.18 (0.37; 2.54) 0.45 1 1.28 (0.70; 4.1) 1.17 (0.44; 2.46) 0.02 1 0.003
p-value are from rank sum Wilcoxon test or χ2/Fisher test; Date are medians and 25th to 75th percentiles or % (frequencies)
NRTI: nucleoside reverse-transcriptase inhibitor; NNRTI: non-nucleoside reverse-transcriptase inhibitor; PI: protease inhibitor
1 p-values adjusted for sex
2 patients with >200/mm3 CD4 T-cell counts (group1) vs. patients with 200/mm3 CD4 T-cell counts (group2) at ART initiation
doi:10.1371/journal.pone.0144317.t001
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patients in group 1 gained significantly more weight during ART than patients in group 2
(p<0.0001).
At ART initiation, total and LDL-cholesterol levels tended to be lower in group 1 than in
group 2 (p values adjusted for sex = 0.12 and 0.06, respectively). HDL-cholesterol levels were
also lower in group 1 (p value adjusted for sex = 0.01), while triglyceride levels were higher (p
value adjusted for sex = 0.04). About 7% of patients in both groups started lipid-lowering ther-
apy during ART. At three years, total, HDL- and LDL-cholesterol levels increased in both
groups and no longer differed according to the initial CD4+ cell count. Triglyceride levels did
not change notably in either group during the three years of follow-up, and thus remained
higher in group 1 than in group 2.
The proportion of patients with impaired fasting glucose metabolism or diabetes did not dif-
fer between the two groups at ART initiation or at three years, and neither did the median fast-
ing glucose level. The fasting insulin level tended to be higher in group 1 at ART initiation
(p = 0.09) and was significantly higher after three years. (8.9 vs 7.2 mU/l, p = 0.01). Fasting glu-
cose values did not change significantly in either group.
Adiponectin levels tended to be lower in group 1 than in group 2, both at ART initiation
and at three years (p = 0.10 and 0.10, respectively). Adiponectin levels improved significantly
on ART in group 2 but not in group 1. As expected, serum leptin levels varied according to
BMI; they increased in both groups, but significantly more markedly in group 1 than in group
2. This led to a significant difference in the leptin/adiponectin ratio after 3 years of ART, which
became higher in group 1 than in group 2 (1.28 vs. 1.17, p value = 0.003). Thus, more severe
immune deficiency at ART initiation was associated with lower insulin sensitivity after three
years of ART.
Factors associated with diminished insulin sensitivity (Table 2)
We then used univariate and multivariate linear variation analyses to study the role of selected
factors in the diminished insulin sensitivity, based on insulin levels after three years of ART
(Table 2). These analyses involved the 194 patients for whom complete data were available. In
univariate analysis, patients with low CD4+ cell counts ( versus> 200), an insulin level above
10 mIU/L at ART initiation, or a large increase in BMI (as a continuous variable) after three
years of ART were more likely to have elevated insulin levels after three years of ART
(p = 0.006, 0.002 and 0.003, respectively). Patients still exposed to ZDV at three years had
higher insulin levels than patients never/no longer exposed to ZDV (p = 0.003), while those
still exposed to a PI at three years of ART tended, but not significantly, to have higher insulin
levels than patients never/no longer exposed to a PI (p = 0.10).
After adjustment for geographic origin, sex, age at ART initiation, BMI after three years of
ART and ongoing exposure to ZDV (model 2) or PIs (model 3), insulin levels after three years
of ART remained higher in group 1 than in group 2 (p = 0.04 and 0.02, respectively), indicating
that an initial CD4+ cell count 200/mm3 is a risk factor for an altered insulin sensitivity after
3 years of successful ART. Similar results were obtained when only patients with VL< 50 cop-
ies/mL at three years of ART were taken into account.
Markers of inflammation and immune activation (Fig 1)
At ART initiation, levels of IL-6 and sTNFRII were higher in group 1 than in group 2
(p = 0.0009 and<0.0001, respectively), whereas hsCRP levels did not differ. During the three
years of ART, the levels of these markers evolved differently. IL-6 levels tended to decline in
both groups but remained higher in group 1 than in group 2 (p = 0.03). sTNFRI and sTNFRII
fell significantly, to similar levels in the two groups. Levels of hsCRP were unmodified in group
Late ART Initiation, Inflammation and Metabolism
PLOSONE | DOI:10.1371/journal.pone.0144317 December 4, 2015 6 / 15
1 but fell significantly in group 2 (p = 0.03). Thus, after 3 years of ART, the hsCRP level tended
to be higher in group 1 than in group 2 (p = 0.07).
In group 1, sCD14 levels, which were higher than in group 2 at ART initiation, fell to values
similar to those observed in group 2 at ART initiation and after three years of ART. sCD163
levels were high at ART initiation in both groups and declined to similar levels after 3 years of
ART (p = 0.55). Of note, higher insulin levels at 3 years of ART were associated with higher
hsCRP and sCD163 levels, even in patients with undetectable VL, while other parameters were
not linked to insulin levels (data not shown).
Discussion
Several cross-sectional studies have shown a relationship between insulin sensitivity and the
CD4+ cell count, both in ART-naïve patients and in patients on ART [14, 31, 35, 36]. However,
to our knowledge, this is the first study to simultaneously evaluate changes in insulin sensitivity
and markers of immune activation and inflammation during long-term ART.
We examined changes in insulin sensitivity and markers of inflammation and immune acti-
vation in HIV-infected patients according to their CD4+ cell count at ART initiation
( or> 200 cells/mm3). After three years of successful ART, patients who had been pro-
foundly immunodeficient owing to late ART initiation had lower CD4+ cell counts and CD4/
CD8 ratios and, importantly, lower insulin sensitivity and higher circulating IL-6 levels (with a
trend towards higher hsCRP levels) than patients in the same cohort who were less severely
immunodeficient at ART initiation.
Table 2. Univariate andmultivariate linear regression analysis: role of several parameters on insulin levels after 3 years of ART in HIV-1 infected
patients from the ANRS CO9 COPANA Cohort.
Univariate (n = 194) Multivariate (n = 194)
Model 1 Model 2 Model 3
Characteristics β
coefﬁcient*
P-
value
β
coefﬁcient*
P-
value
β
coefﬁcient*
P-
value
β
coefﬁcient*
P-
value
CD4+ T-cell counts  200 /mm3 at ART
initiation (group 1 vs group 2)
+ 3.32 0.006 + 2.86 0.02 + 2.46 0.04 + 2.71 0.02
Geographic origin: sub-Saharan Africa (vs.
others)
+ 0.44 0.71 - 0.82 0.53 - 0.69 0.59 - 0.79 0.55
Female sex (vs. male) + 0.07 0.95 - 0.65 0.62 - 0.56 0.67 - 0.80 0.55
Age at ART initiation (for an increase of 1 year) - 0.04 0.45 - 0.10 0.07 - 0.10 0.06 - 0.10 0.07
Insulin at ART initiation > 10 mIU/L (vs.  10
mIU/L)
+ 4.08 0.002 + 3.00 0.02 + 2.41 0.06 + 2.94 0.02
BMI at 3 years of ART (for an increase of 1 kg/
m2)
+ 0.40 0.003 + 0.39 0.005 + 0.47 0.001 + 0.39 0.006
ZDV exposure at 3 years
0 or < 1 month ref ref
Interrupted - 1.25 0.41 - 2.17 0.15
Still exposed + 3.50 0.03 + 2.57 0.10
PI exposure
0 or < 1 month ref ref
Interrupted + 0.60 0.77 + 0.24 0.89
Still exposed + 2.20 0.10 + 1.50 0.24
* From linear regression model: the model provides the difference in mean insulin levels between the modalities of a variable
doi:10.1371/journal.pone.0144317.t002
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Fig 1. Distribution of inflammatory markers according to CD4 T cell count at ART initiation.
doi:10.1371/journal.pone.0144317.g001
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At 3 years, total, LDL- and HDL-cholesterol levels no longer differed between patients with
baseline CD4+ cell counts below and above 200/mm3, related to virologic suppression and
immune restoration. In contrast, triglyceride levels remained higher in the patients who were
more immunodeficient at ART initiation, even though similar proportions of patients in the
two groups received PI-based ART. These results are in keeping with those of previous studies
showing that HIV infection alters the lipid profile, notably with low cholesterol and high tri-
glyceride levels [31–32], and that these lipid alterations are linked to immune deficiency and/or
HIV replication, independently of cachexia and major weight loss [15].
We previously showed that insulin sensitivity was more strongly impaired in severely
immunodeficient ART-naïve patients than in their less immunodeficient counterparts [15]; we
observed the same trend in the present group which originates from the same cohort. Further-
more, other studies showed similar results [31, 33]. Importantly, after three years of successful
ART, insulin levels were higher in patients who started treatment at low CD4+ cell counts
( 200/mm3). This difference persisted after taking into account other factors that might influ-
ence glucose metabolism, such as gender, geographic origin, the initial insulin level, and BMI
and even after taking into account the use of PIs or ZDV, which are known to increase the risk
of insulin resistance and diabetes [4, 6, 12, 34]. Thus, three years of effective ART had little
impact on insulin resistance associated with pretreatment immunodeficiency.
Markers of inflammation and immune activation improved during ART. Interestingly, after
3 years of successful ART, hsCRP and hsIL-6 levels were similar to those we recently observed
in another cohort of patients on long-term effective ART (APROCO-COPILOTE), which were
relatively low but higher than in uninfected subjects [21]. As expected, markers of inflamma-
tion and immune activation were more markedly elevated in the patients who were most
immunocompromised before starting ART. After three years of ART, even if CD4+ cell counts
remained lower in patients with lower pretreatment counts, the level of these markers no lon-
ger differed between the groups, arguing for a major role of the viral suppression that drives
immune restoration. Nevertheless, hsIL-6 and, marginally, hsCRP levels remained elevated,
indicating persistent low-grade systemic inflammation in patients with lower CD4 counts at
ART initiation.
Few studies have focused on markers of inflammation and immune activation according to
the CD4+ cell count or HIV viral load. In the Veterans Aging Cohort Study (VACS) [37], IL-6
and sCD14 levels were higher in ART-naïve patients with CD4+ cell counts< 200/mm3, and
this remained true for ART-treated patients whose CD4+ cell count remained below 200/mm3.
We have also previously observed that TNF-α, sTNFRI, sTNFRII and IL-6 levels are inversely
related to the CD4+ cell count in ART-naïve patients [15]. The level of IL-6 was previously
shown to be related to the CD4 nadir and to high levels viral load [20]. It should be noted, how-
ever, that these studies were cross-sectional and did not therefore analyze changes after ART
initiation.
Changes in markers of inflammation and immune activation during ART have been widely
studied. IL-6 levels fell in two studies of patients with initial median CD4+ cell counts of respec-
tively 240/mm3 [38] and 315/mm3 [39], while they did not change in another study in which
the initial median CD4+ cell count was higher (431/mm3) [40]. sTNFRI and sTNFRII levels fell
after 96 weeks of ART [38], whereas CRP levels did not change [38–40]. ART was associated
with an improvement in the activation markers sCD14 and sCD163 [41–42]. However, these
studies did not interpret changes in marker levels according to the initial CD4+ cell count. Our
results, showing similarly elevated sCD14 levels after three years of successful ART in patients
with pre-ART CD4 cell counts above and below 200/mm3, are in keeping with reports that
control of HIV replication does not totally suppress gut barrier alterations and microbial trans-
location, which are important drivers of persistent immune activation [22]. Chronic monocyte
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activation, associated with persistent low-grade systemic inflammation in patients with lower
CD4 counts at ART initiation, probably plays a role in their lower insulin sensitivity, as sug-
gested by the association between insulin levels at 3 years of ART and higher hsCRP and
sCD163 levels. This is in accordance with previous studies showing that insulin resistance is
associated with immune activation in the general population [43].
Compared with historic studies using first-generation PIs such as indinavir, insulin resis-
tance was moderate and the incidence of diabetes was low in our cohort, in keeping with the
use of more recent ART regimens. In addition, levels of inflammatory markers after 3 years of
effective ART were not very high, except for sCD14, which remained elevated regardless of the
pre-ART CD4 cell count. One limitation of our study is that the two groups of patients were
not included during the same calendar periods, due to the evolving recommendations in the
CD4 criteria of ART initiation, and thus that the ART combinations were different. We have
carefully adjusted for these ART differences in our study and show that the differences in insu-
lin sensitivity persisted.
In conclusion, we found that markers of metabolic abnormalities and inflammation
remained elevated, albeit moderately, after 3 years of successful ART in patients who started
ART at low CD4 cell counts. These persistent abnormalities are known to be associated with an
increased long-term risk of cardiovascular and metabolic disease. It remains to be seen whether
these patients ultimately recover marker values similar to those observed in patients who begin
ART at higher CD4 cell counts.
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